BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38365483)

  • 1. Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Mziou E; Hchaichi A; Letaief H; Dhaouadi S; Safer M; Talmoudi K; Mhadhbi R; Elmili N; Bouabid L; Derouiche S; Bougatef S; Bellali H; Bouafif Ép Ben Alaya N
    Vaccine; 2024 Mar; 42(7):1738-1744. PubMed ID: 38365483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study.
    Lang AL; Hohmuth N; Višković V; Konigorski S; Scholz S; Balzer F; Remschmidt C; Leistner R
    J Med Internet Res; 2024 Jun; 26():e47070. PubMed ID: 38833299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
    Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
    JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
    Barchuk A; Cherkashin M; Bulina A; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
    BMC Med; 2022 Sep; 20(1):312. PubMed ID: 36123681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
    Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
    BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
    Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
    PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
    Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
    BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.
    Khan UI; Niaz M; Azam I; Hasan Z; Hassan I; Mahmood SF; Ali A
    BMJ Open; 2023 Jun; 13(6):e071789. PubMed ID: 37369396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Urquidi C; Santelices E; Lagomarcino AJ; Teresa Valenzuela M; Larrañaga N; Gonzalez E; Pavez A; Wosiack A; Maturana M; Moller P; Pablo Torres J; Muñoz S; O'Ryan G M
    Vaccine; 2023 May; 41(18):2947-2955. PubMed ID: 37024408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Turbyfill C; Adams K; Tenforde MW; Murray NL; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Clark Files D; Hager DN; Shehu A; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; June Gordon A; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Rhoads JP; Lindsell CJ; Hart KW; McMorrow M; Surie D; Self WH; Patel MM
    Vaccine; 2022 Nov; 40(48):6979-6986. PubMed ID: 36374708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.